Sterile Supply Recall Watch: Baxter, Medline-BD Lots

Sterile Supply Recall Watch: Baxter Dextrose, Medline–BD ChloraPrep Kits, and What Wound Clinics Should Do Now

Late August 2026 brought a dense cluster of FDA recalls and alerts touching the exact supplies wound and infusion clinics use every week: a parenteral-nutrition diluent, apheresis anticoagulant, convenience kits built around recalled skin-prep applicators, and a Class I percutaneous catheter. None is a wound-care product in the narrow sense — but every one circulates through wound centers that run infusion suites, procedural debridements, and vascular access lines. The clinical through-line is particulate and fungal contamination risk at the point of sterile delivery, and a pattern this concentrated deserves a standing recall-watch workflow, not four separate fire drills.

What Was Recalled: The August 2026 Cluster

| Recall / alert | Product and identification | Hazard | Action required | |---|---|---|---| | Baxter 70% Dextrose Injection | Product code 2B0296H, lot Y495066, exp. 31-Jul-2027, NDC 0338-0719-06; 2000 mL VIAFLEX pharmacy bulk package | Stainless-steel particulate matter; risk of vascular blockage, clotting, pulmonary embolism, organ damage | Discontinue and return; notify patients if lot was used to compound PN | | Baxter Anticoagulant Sodium Citrate Solution | Product code 2B7867Q, lot Y493475, exp. 31-Dec-2027, NDC 0338-9669-01; 250 mL VIAFLEX, for apheresis devices | Fiberglass particulate matter; vein irritation, embolic risk without in-line filtration | Discontinue and return | | Medline convenience kits (FDA Early Alert) | Kits containing BD ChloraPrep item 930480 lot 4032183 (Clear 1 mL applicators) and item 930299 lot 4073005 (FREPP Clear 1.5 mL, paper lidding) | Fungal contamination (Aspergillus penicillioides) under certain environmental conditions; systemic infection, sepsis risk | Review inventory, quarantine, destroy entire kit after response forms | | Boston Scientific ENROUTE Transcarotid Neuroprotection System (NPS / NPS Plus) | Specific lots (full list on FDA page); may appear in inventory under legacy Silk Road Medical names | Arterial sheath tip separation; embolism, stroke, TIA, restenosis, thrombosis risk. Class I recall | Do not use; identify, cease use and distribution, return to Boston Scientific |

All four notices state no deaths had been reported as of their publication dates. The Baxter and Medline actions posted the week of August 24–31, 2026; the ENROUTE recall was elevated to Class I on August 26, with customer letters dating to July 9.

Distribution scope matters for triage. Baxter distributed the dextrose lot between July 25 and July 28, 2026 to healthcare providers and distributors in Alabama, Georgia, and Tennessee; the sodium citrate lot went to a single customer in the United States. A facility outside those channels can clear its lot sweep quickly — but still log the zero-find, because recall scope expands when new distribution data arrive.

Why Particulate Recalls Matter More in a Wound Clinic Than a Hospital Pharmacy

The Baxter dextrose recall is a single-lot event, but the hazard class deserves attention beyond the affected carton. Intravenous particulate matter is well characterized: particles can obstruct small vessels, nucleate clots, and trigger inflammatory reactions. FDA recall analysis shows contamination events — particulates, microbial, impurities — recur as a structural feature of sterile manufacturing, not isolated accidents (PMID 26843501), and fungal contamination of injectable drugs remains a recurring recall trigger (PMID 29420758).

For the dextrose lot, the exposure pathway that matters most to wound clinics is compounding: 70% dextrose is mixed with amino acids for parenteral nutrition. Baxter directs facilities that compounded PN with lot Y495066 to contact patients and tell them to discontinue the solutions — a patient-notification burden that falls on the compounder, not the shelf. Trace the lot through every compounded bag before returning stock. The standard mitigation for IV particulate risk in PN is in-line filtration, which ASPEN recommends as a routine safeguard (PMID 33091206); if your infusion practice does not filter PN lines, this recall is the prompt to review that policy independent of whether you held the affected lot.

The sodium citrate recall follows the same logic in a different device context: the solution is intended only for automated apheresis devices, and without in-line filtration the risk calculus is identical — local vein irritation, hypersensitivity, and systemic embolization.

The Medline–BD ChloraPrep Alert: When the Kit Is the Recall Unit

The Medline Early Alert escalates a pattern wound centers navigated once already this summer. Certain Medline convenience kits contain BD ChloraPrep applicators — item 930480, lot 4032183 (Clear 1 mL) and item 930299, lot 4073005 (FREPP Clear 1.5 mL, paper lidding) — subject to BD's own recall for potential Aspergillus penicillioides contamination. Medline's August 11 letter changes the required action from the earlier June 12 notification: affected kits should now be quarantined and the entire kit destroyed after completion of response forms. Over-labels from the earlier action instructing users to remove the affected component at point of use are superseded for these lots.

The organism is worth naming precisely. Aspergillus penicillioides is a xerophilic mold capable of growth at extremely low water activity (PMID 27871132) — which is why it can persist in a nominally dry applicator, and why "the kit looked fine" is not evidence of safety. If introduced into the bloodstream during catheter placement, FDA notes the catheter would likely need removal, an additional procedure, and possibly prolonged antifungal therapy. Serious fungal contamination of pharmaceuticals and devices has been a recurring driver of clinical harm and rapid-detection research (PMID 37978091).

For wound clinics, the operational burden is a double lookup: the kit-level Medline catalog item in your inventory system, and the component-level BD lot inside it. If you already completed the June 12 Medline response, you are not done — the August 11 letter changes the disposition for certain lots. Recheck against the current FDA alert, not your first-pass file.

The ENROUTE Class I Recall: Relevant to Vascular-Access-Heavy Practices

Boston Scientific's removal of specific ENROUTE NPS and NPS Plus lots for arterial sheath tip separation is a neuro-interventional device, not stocked in most wound centers — but devices may still appear in inventory under legacy Silk Road Medical names. Practices hosting vascular or interventional procedures should reconcile inventory under both manufacturer names. One serious injury and no deaths were reported as of July 9.

A Standing Recall-Watch Workflow

Four notices in one week is the new baseline — FDA drug-recall categorization work shows recalls cluster by predictable failure modes (PMID 35422393), so a fixed workflow absorbs each notice in minutes instead of hours. Adapted from our component-recall verification workflow for the BD convenience kit advisory and the standing 30-minute device recall response SOP:

1. Subscribe to the sources once, centrally. FDA drug and device recall feeds plus MedWatch alerts, routed to a named owner, not an inbox. 2. Run a lot-level sweep on every notice, even single-lot ones. Match NDC or product code first, then confirm lot and expiration across central supply, procedure rooms, case carts, consignment, and off-site stock. For kits, look up both the kit catalog number and the component lot inside it — they may live in different systems. 3. Quarantine with documentation before disposition. Hold, label, and log the lot, including a zero-find record — it matters if the recall widens. 4. Trace exposures downstream before returning product. For compounded products (the dextrose lot), determine whether affected lots entered compounded bags and who received them; that drives the patient-notification decision. 5. Close the loop with the manufacturer letter and response form. The Medline action requires response forms and whole-kit destruction — disposition is not complete until the form is filed.

Frequently Asked Questions

No. Both actions are lot-specific: only dextrose lot Y495066 and Medline kits containing BD ChloraPrep lots 4032183 or 4073005. Verify by lot number, not by brand.

Yes. The required action for certain lots changed: quarantine the kit and destroy it entirely after completing response forms, rather than removing the affected component at point of use. The August 11 letter controls.

Baxter directs facilities that compounded PN with the affected lot to contact patients and tell them to discontinue the solutions. Trace lot Y495066 through your compounding log before returning stock, and follow your patient-communication protocol for any affected bags.

Probably not — it is a transcarotid neuroprotection system for carotid stenting. If your practice stocks or hosts vascular procedures, check inventory under both Boston Scientific and legacy Silk Road Medical names.

ASPEN recommends in-line filtration as a routine safety practice for PN delivery, independent of any single recall (PMID 33091206). Whether your current filter policy matches that recommendation is worth a pharmacy review now rather than during the next recall.

Adverse reactions or quality problems go to FDA MedWatch; direct product questions to the manufacturer contact in each notice (Baxter 888-229-0001; Medline 866-359-1704 or [email protected]; Boston Scientific (763) 415-7708).

Compliance Note

This article is an educational operational advisory for wound and infusion clinic procurement, clinical, and quality staff, based on FDA recall notices and manufacturer communications published in late August 2026. It is not legal advice and does not establish a standard of care. Recall classifications, affected-lot lists, and recommended actions change as FDA review continues; verify the current FDA notice and manufacturer letter before acting.

References

1. U.S. Food and Drug Administration. Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection Due to Potential Presence of Particulate Matter. Company announcement, August 25, 2026. fda.gov/safety/recalls-market-withdrawals-safety-alerts. 2. U.S. Food and Drug Administration. Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution Due to Potential Presence of Particulate Matter. Company announcement, August 25, 2026. fda.gov/safety/recalls-market-withdrawals-safety-alerts. 3. U.S. Food and Drug Administration. Early Alert: Convenience Kit Issue from Medline. CDRH Medical Device Recalls and Early Alerts, content current as of August 24, 2026. fda.gov/medical-devices/medical-device-recalls-and-early-alerts. 4. U.S. Food and Drug Administration. Percutaneous Catheter Recall: Boston Scientific Removes ENROUTE Transcarotid Neuroprotection System. Classified as Class I, August 26, 2026. fda.gov/medical-devices/medical-device-recalls-and-early-alerts. 5. Worthington P, et al. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper. Nutr Clin Pract. 2021. PMID 33091206. 6. Hall K, et al. Characteristics of FDA drug recalls: A 30-month analysis. Am J Health-Syst Pharm. 2016. PMID 26843501. 7. Ahearn DG, et al. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing. Med Mycol. 2018. PMID 29420758. 8. Stevenson A, et al. Aspergillus penicillioides differentiation and cell division at 0.585 water activity. Environ Microbiol. 2017. PMID 27871132. 9. Ahmed MAEE, et al. Fungal diseases caused by serious contamination of pharmaceuticals and medical devices, and rapid fungal detection methods. Curr Microbiol. 2023. PMID 37978091. 10. Mattingly AN, et al. Categorization and comparisons of drug recalls for manufacturers and compounders. J Am Pharm Assoc. 2022. PMID 35422393.

Related Resources

- BD Convenience Kit Early Alert: What Wound Centers Should Check Now - Quality Assurance for Wound Biologics: Independent Testing and Supply Chain Integrity - Reimbursement and Coding for Amniotic Membrane Allografts: 2026 Update - Wound Center Device Recall Response: A 30-Minute SOP - Wound Biologics HCPCS Codes: Q-Codes, Modifiers, Pitfalls